ATS 2024 Final Program

Click on the session title to view the speakers

301

TUESDAY • MAY 21

413 The Orai1 Antagonist, ELD607, Reduces Chronic Neutrophilic Inflammation in ßENaC Mice 414 CX 3 CR1 Expression Defines a Subset of Type 2 Conventional Dendritic Cells 415 Opposing Roles of Neutrophils in Promoting Versus Protecting Against Pathology in Lung Injury 416 Oxidative Stress-induced S-glutathionylation of Gasdermin D in Macrophages Protects Against Sepsis 417 STAT1 Regulates Pro-survival SLC7A11 and Limits Monocyte Accumulation in Lung Injury 418 The Nasal Mucosa of the CFTR-KO Mouse Mimics Baseline Cystic Fibrosis Immune Dysregulation and Microbiome Dysbiosis 419 Sex-dependent Inflammatory Immune Cell Recruitment to the Lungs and Airways in Mice With HIF1a and HIF2a Knocked-out in Pulmonary Endothelial Cells 420 Human Infants Exhibiting Heightened Airway Epithelial IL-1ß Responses Demonstrate Primed Neutrophilic Airway Reactivity and Nucleosome Activation 421 RLS-0071 Independently Inhibits Neutrophil Migration and Myeloperoxidase Activity and NETosis in Humans Challenged With LPS by Inhalation 422 Lung Microbiota Influence Responses to Anti-PD1 Therapy in a Preclinical Model of Non-small Cell Lung Cancer 423 Megakaryocytes Localize to Regions of Inflammatory Foci in Human Lung Tissue 424 Comparative Analysis of Antibiotic Resistance Gene Profiles in Adults With Cystic Fibrosis With and Without Diabetes 425 Patients on Benralizumab, Dupilumab, or Mepolizumab Have Lower Post-vaccination SARS-CoV-2 Immunity

BASIC • CLINICAL • TRANSLATIONAL RAPID POSTER DISCUSSION SESSION

C102 CLINICAL AND TRANSLATIONAL ADVANCES IN ASTHMA 2:15 p.m. - 4:15 p.m.

San Diego Convention Center Room 28C-E (Upper Level)

Viewing/Discussion Abstract Summaries

2:15-3:00

3:00-4:15 301 Reduced Mucus Plugging With Tezepelumab Is Spatially Associated With Reduced Air Trapping in a Broad Population of Patients With Moderate to Severe Asthma 302 Comparative Burden of Disease Associated With Short-acting Beta 2 -agonist and Systemic Corticosteroid Exposures in US Children, Adolescents, and Adults With Asthma 303 Longitudinal Clinical Course of Participants With Asthma in Severe Asthma Research Program (SARP) Cohort 304 Dupilumab Asthma ADVANTAGE-EU: Real-World Evidence on the Association Between Dupilumab and Use of Corticosteroid and Asthma Exacerbations in Patients With Severe Asthma in Europe 305 Greater Exacerbation Reductions With Earlier Biologic Initiation After Severe Asthma Onset: Results From the Chronicle Study 306 Development and Validation of an Individualised Risk Prediction Model for Exacerbations in Patients With Severe Asthma in Real-world Settings 307 Serial Effects of Dupilumab on Mannitol Airway Hyperresponsiveness in Uncontrolled Severe Type 2 High Asthma 308 Effects of Mepolizumab in a Pediatric Population With Severe Asthma: Pharmacological Modeling, Simulation and Extrapolation of Data From Adult Patients 309 Implementing the Asthma Impairment and Risk Questionnaire (AIRQ ® ) and Asthma Checklist in Primary and Specialty Care Practices: Effects on Exacerbation Occurrence

ATS 2024 Conference Program • San Diego, CA